3 ms·
Seconded. I am very interested in learning more about this question.
by ddingus 11y ago
Seconded. I am very interested in learning more about this question.
- refurb 11y agoI'm in the biotech business and I've never heard of the first option in France at all. That said, individual countries regulations can be quite complex, so it might be true. As for the second option, France, Germany and the UK all have a system where an independent body evaluates a drug in order to determine it's value. They do this by comparing the new drug against what's currently available and provide a rating. In France it's an ASMR rating, but I think that's changing. Once the drug receives a rating (Important, moderate, mild and insufficient improvement over current agents, ASMR I-IV), the company and gov't enter negotiations over the price.[1] [1] http://www.has-sante.fr/portail/upload/docs/application/pdf/2014-03/pricing_reimbursement_of_drugs_and_hta_policies_in_france.pdf http://www.has-sante.fr/portail/upload/docs/application/pdf/...